Inhibition of CD44 suppresses the formation of fibrotic scar after spinal cord injury via the JAK2/STAT3 signaling pathway
iScience, 2024 · DOI: https://doi.org/10.1016/j.isci.2024.108935 · Published: February 16, 2024
Simple Explanation
This study investigates the role of CD44 in fibrotic scar formation after spinal cord injury (SCI). It found that CD44 expression increases during scar formation. Blocking CD44 with the IM7 antibody reduces the expression of fibrosis-related proteins and promotes axon regeneration across the scar. The study also explores the underlying mechanisms, revealing that CD44 influences fibrotic scar formation via the JAK2/STAT3 signaling pathway in an inflammatory environment.
Key Findings
- 1CD44 is upregulated during the formation of fibrotic scar after spinal cord injury.
- 2Blocking CD44 with IM7 reduces fibrosis-related extracellular matrix protein expression and promotes corticospinal tract axon regeneration across the scar.
- 3CD44 modulates fibrotic scar formation in the inflammatory microenvironment via the JAK2/STAT3 signaling pathway.
Research Summary
Practical Implications
Therapeutic Target Identification
CD44 and its downstream JAK2/STAT3 signaling pathway are potential therapeutic targets for treating fibrotic scar formation after SCI.
Functional Recovery Improvement
Targeting CD44 can promote axon regeneration and improve motor and sensory function recovery after spinal cord injury.
Inflammatory Microenvironment Modulation
Modulating the inflammatory microenvironment by inhibiting CD44 may provide a strategy to reduce fibrotic scar formation and enhance functional recovery.
Study Limitations
- 1JAK2/STAT3 signaling may not be the sole pathway implicated in CD44-mediated fibrosis.
- 2Certain fibrosis-related proteins did not return to the control level in the presence of an inflammatory microenvironment, despite the inhibition of this pathway.
- 3Further investigations are warranted to substantiate whether other concurrent molecular pathways may be involved in this process.